Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 17/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.57 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.57 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838239 | 0.90 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL838144 | 0.90 | ADORA2B (0.57) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL242945 | 0.89 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL839349 | 0.88 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL839622 | 0.88 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL29403125 | 0.88 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL241951 | 0.88 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL238938 | 0.88 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL839135 | 0.87 | ADORA2B (0.60) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL797120 | 0.87 | ADORA2B (0.47) | ADORA2BADORA2AADORA1ADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143249-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2301937-A1 | Prodrugs of A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.